TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Exclusion Criteria

• •History of established diagnosis of tardive dyskinesia
• •Clinical evidence of unstable medical or psychiatric illness
• •Clinically significant active and unstable psychotic disease (hallucinations or delusions)
• •Major depression (Beck Depression Inventory \[BDI\]-II Score greater than 20) at Screening Visit
• •Suicidal ideation (BDI-II item 9 greater than or equal to 2) at Screening Visit
• •History of clinically significant substance abuse within 12 months of Baseline Visit
• •Pregnant/lactating women
• •Participation in other drug studies within 60 days prior to Baseline Visit
• •Previous participation in any investigational study of ethyl-EPA (Miraxion™)
• •Use of aspirin at daily dosage greater than 325 mg/day
• •Exclusionary Drugs (within 6 months Baseline Visit): Depot neuroleptics
• •Exclusionary Drugs (within 60 days Baseline Visit): Omega-3 supplementation, tetrabenazine or reserpine, high dose and/or variable dose oral anti-psychotic medications, steroid (other than topical), selenium supplements greater than 55 mcg/day, lithium, benzodiazepines (except for low dose), anticoagulants